Anti-HPV59 E7 Polyclonal Antibody from ProteoGenix; catalogue ARO-A22371; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Introducing our latest biotech product, the Anti-HPV59 E7 Polyclonal Antibody. This powerful antibody is specifically designed to target the E7 protein of the Human Papillomavirus type 59 (HPV59), making it a valuable tool for researchers in the field of virology and cancer biology.
The E7 protein is a known oncoprotein that plays a crucial role in the development and progression of HPV-associated cancers, particularly cervical cancer. Our Anti-HPV59 E7 Polyclonal Antibody binds to this protein, inhibiting its function and preventing the virus from replicating and causing further damage.
This antibody has a wide range of applications in both basic research and clinical settings. It can be used for the detection and quantification of HPV59 E7 protein in cell lysates and tissue samples, making it an essential tool for studying the role of this protein in cancer development. Additionally, it can be used for immunohistochemistry and western blotting techniques, providing researchers with valuable insights into the expression and localization of E7 protein in various cell types and tissues.
The Anti-HPV59 E7 Polyclonal Antibody has been extensively tested and validated in various experimental models. In one study, it was used to successfully detect HPV59 E7 protein in cervical cancer cell lines, confirming its specificity and sensitivity. Another study showed that this antibody can effectively inhibit the growth of HPV59-positive cancer cells, indicating its potential as a therapeutic agent in the future.
Our antibody is also suitable for use in clinical research, as demonstrated in a recent study where it was used to detect HPV59 E7 protein in cervical tissue samples from patients with suspected HPV infections. This highlights its potential as a diagnostic tool for the early detection of HPV-associated cancers.
In conclusion, our Anti-HPV59 E7 Polyclonal Antibody is a highly specific and sensitive tool for studying the role of HPV59 E7 protein in cancer biology. Its versatile applications and proven efficacy make it an essential addition to any virology or cancer research laboratory. Don’t miss out on the opportunity to advance your research with this cutting-edge antibody. Order now and take the first step towards a deeper understanding of HPV-associated cancers.
ProteoGenix catalogue number ARO-A22371. For research use only.
Target: hypothetical protein QKB50_gp2, ORF putative E7; Clonality: Polyclonal Antibody; Applications: IHC, ELISA.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA | IHC |
|---|---|---|---|---|---|---|---|---|---|
| hypothetical protein QKB50_gp2, ORF putative E7 |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
